Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CEO Sells 2,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $9.09, for a total value of $18,180.00. Following the completion of the transaction, the chief executive officer now owns 14,609,662 shares in the company, valued at $132,801,827.58. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 13th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.37, for a total value of $16,740.00.
• On Friday, November 8th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.77, for a total transaction of $17,540.00.
• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.82, for a total transaction of $17,640.00.
• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.67, for a total transaction of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total value of $17,840.00.

Zynex Stock Down 5.1 %

Shares of Zynex stock traded down $0.44 during trading on Wednesday, hitting $8.13. 110,766 shares of the stock were exchanged, compared to its average volume of 170,433. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The firm’s 50-day moving average price is $8.22 and its 200 day moving average price is $8.92. The stock has a market cap of $258.94 million, a price-to-earnings ratio of 54.20 and a beta of 0.53. Zynex, Inc. has a 12-month low of $7.15 and a 12-month high of $13.77.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The company had revenue of $49.97 million during the quarter, compared to the consensus estimate of $50.83 million. During the same period in the previous year, the business earned $0.10 EPS. Zynex’s revenue for the quarter was up .1% on a year-over-year basis. As a group, analysts forecast that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zynex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZYXI. Gladius Capital Management LP boosted its stake in Zynex by 53.4% in the third quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock valued at $41,000 after acquiring an additional 1,742 shares in the last quarter. Principal Financial Group Inc. grew its position in Zynex by 10.4% during the 2nd quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after purchasing an additional 1,846 shares during the last quarter. Cim LLC increased its stake in Zynex by 6.1% in the second quarter. Cim LLC now owns 43,581 shares of the company’s stock valued at $406,000 after purchasing an additional 2,508 shares during the period. American Century Companies Inc. raised its holdings in shares of Zynex by 10.1% in the second quarter. American Century Companies Inc. now owns 31,159 shares of the company’s stock valued at $290,000 after buying an additional 2,864 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Zynex by 1.6% during the second quarter. Bank of New York Mellon Corp now owns 192,832 shares of the company’s stock worth $1,797,000 after buying an additional 2,954 shares during the period. 29.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. HC Wainwright lifted their target price on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Royal Bank of Canada cut their target price on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.